The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies.

Comprehensive directory of diagnostic deals since 2007
Diagnostic contract documents
Diagnostic agreement terms
Diagnostic agreement structure
Top diagnostic deals by value
Most active diagnostic dealmakers The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all diagnostics partnering deals announced since January
2007, including financial terms where available, including over 3,000 links to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in diagnostics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading diagnostics deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document,
providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and
specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in diagnostics
partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of diagnostics technologies and products.

Report scope
Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide.

Diagnostics Partnering Terms and Agreements includes:

Trends in diagnostic dealmaking in the biopharma industry since 2007
Analysis of diagnostic deal structure
Case studies of real-life diagnostic deals
Access to over 2,900 diagnostic contract documents
The leading diagnostic deals by value since 2007
Most active diagnostic dealmakers since 2007
The leading diagnostic partnering resources
In Diagnostics Partnering Terms and Agreements , the available contracts are listed by:

Headline value
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via Weblink to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Diagnostics Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of diagnostic deal trends since 2007
Analysis of the structure of diagnostic agreements with numerous real life case studies
Comprehensive access to over 2,900 actual diagnostic contracts entered into by the world’s biopharma companies
Detailed access to actual diagnostic contracts enter into by the leading fifty bigpharma companies
Insight into the terms included in a diagnostic agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
 

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in diagnostic dealmaking

2.1. Introduction
2.2. Diagnostic partnering over the years
2.3. Most active diagnostic dealmakers
2.4. Bigpharma diagnostic dealmaking activity
2.5. Bigpharma not active in diagnostics
2.6. Diagnostics partnering by deal type
2.7. Diagnostics partnering by stage of development
2.8. Diagnostics partnering by disease type
2.9. Average deal terms for diagnostics partnering
2.9.1 Diagnostics partnering headline values
2.9.2 Diagnostic deal upfront payments
2.9.3 Diagnostics royalty rates
2.10. The anatomy of diagnostic partnering
2.10.1. The anatomy of a diagnostic deal
2.10.1.a. Case study 1: Sequenom – Lenetex – January 2007
2.10.1.b. Case study 2: Celera – Siemens Medical Solutions – July 2007
2.10.1.c. Case study 3: US Genomics – Rosetta Genomics – May 2006
2.11. Litigation and settlement in diagnostics
Chapter 3 – Leading diagnostic deals

3.1. Introduction
3.2. Top diagnostic deals by value
3.3. Top diagnostic deals involving bigpharma
3.4. Leading diagnostics M&A deals by value
Chapter 4 – Bigpharma diagnostic deals

4.1. Introduction
4.2. How to use bigpharma diagnostic partnering deals
4.3. Bigpharma partnering company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Warner Chilcott
Watson
Chapter 5 – Diagnostic dealmaking directory

5.1. Introduction
5.2. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
5.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Interests
Joint venture
Licensing
Litigation
Loan
Manufacturing
Manufacturing - OEM
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
5.4. By therapy area
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hematology
Hormonal
Hospital care
Immunology
Infectives
Inflammatory
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Respiratory
Sensory organs
Chapter 6 – Diagnostic partnering resource center

6.1. Online diagnostic partnering
6.2. Diagnostic partnering events
6.3. Further reading on diagnostic dealmaking
Appendices

Appendix 1 – Deal type definitions
Appendix 2 – Example diagnostics partnering agreement

About CurrentPartnering
Recent titles from CurrentPartnering
Order Form – Reports

Table of figures

Figure 1: Diagnostic partnering since 2007
Figure 2: Most active diagnostic dealmakers 2007-2011
Figure 3: Bigpharma – top 50 – diagnostic deals 2007 to 2011
Figure 4: Bigpharma diagnostic deal frequency – 2007 to 2011
Figure 5: Inactive bigpharma in diagnostic dealmaking 2007-2011
Figure 6: Diagnostics partnering by deal type since 2007
Figure 7: Diagnostics partnering by stage of development since 2007
Figure 8: Diagnostics partnering by disease type since 2007
Figure 9: Diagnostics partnering by oncology target since 2007
Figure 10: Diagnostic deals with a headline value – by stage of development
Figure 11: Diagnostic deal headline value distribution – discovery stage, US$million
Figure 12: Diagnostic deal headline value distribution – discovery stage, US$million - detail
Figure 13: Diagnostic deal headline value distribution – preclinical stage, US$million
Figure 14: Diagnostic deal headline value distribution – preclinical stage, US$million
Figure 15: Diagnostic deals with upfront payment values – by stage of development
Figure 16: Diagnostic deal upfront payment distribution – discovery stage, US$million
Figure 17: Diagnostic deal upfront payment distribution – discovery stage, US$million - detail
Figure 18: Diagnostic deals with milestone payments
Figure 19: Diagnostic deal milestone payment distribution, US$million
Figure 20: Diagnostic deals with royalty rates
Figure 21: Components of the typical diagnostic deal structure
Figure 22: Settlement licensing agreements since 2003
Figure 23: Top diagnostic deals by value since 2007
Figure 24: Top diagnostic deals signed by bigpharma value since 2007
Figure 25: Top diagnostic M&A deals by value since 2007
Figure 26: Diagnostic deals by therapy – cardiovascular – 2007 - 2011
Figure 27: Diagnostic deals by therapy – central nervous system – 2007 - 2011
Figure 28: Diagnostic deals by therapy – dental – 2007 - 2011
Figure 29: Diagnostic deals by therapy – dermatology – 2007 - 2011
Figure 30: Diagnostic deals by therapy – gastrointestinal – 2007 - 2011
Figure 31: Diagnostic deals by therapy – genetic disorders – 2007 - 2011
Figure 32: Diagnostic deals by therapy – genitourinary – 2007 - 2011
Figure 33: Diagnostic deals by therapy – hematology – 2007 - 2011
Figure 34: Diagnostic deals by therapy – hormonal – 2007 - 2011
Figure 35: Diagnostic deals by therapy – hospital care – 2007 - 2011
Figure 36: Diagnostic deals by therapy – immunology – 2007 - 2011
Figure 37: Diagnostic deals by therapy – infectives – 2007 - 2011
Figure 38: Diagnostic deals by therapy – inflammatory – 2007 - 2011
Figure 39: Diagnostic deals by therapy – metabolic – 2007 - 2011
Figure 40: Diagnostic deals by therapy – musculoskeletal – 2007 - 2011
Figure 41: Diagnostic deals by therapy – oncology – 2007 - 2011
Figure 42: Diagnostic deals by therapy – ophthalmics – 2007 - 2011
Figure 43: Diagnostic deals by therapy – respiratory – 2007 - 2011
Figure 44: Diagnostic deals by therapy – sensory organs – 2007 - 2011
Figure 45: Online partnering resources
Figure 46: Forthcoming partnering events
Figure 47: Deal type definitions
Figure 48: Diagnostics partnering agreement between Inhibitex and 3M, February 2007